Bradley Burton, PA
Surgical · American Fork, UTNPI 1265861892
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$586
- Astellas Pharma US Inc$460
- Endo Pharmaceuticals Inc.$413
- Sumitomo Pharma America, Inc.$274
- Endo USA, Inc.$203
- Johnson & Johnson$188
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,00295%
- Education$1745%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $586 |
| Astellas Pharma US Inc | 24 | $460 |
| Endo Pharmaceuticals Inc. | 18 | $413 |
| Sumitomo Pharma America, Inc. | 13 | $274 |
| Endo USA, Inc. | 11 | $203 |
| Johnson & Johnson | 6 | $188 |
| Coloplast | 5 | $124 |
| Pfizer | 6 | $124 |
| Antares Pharma, Inc. | 7 | $107 |
| Bayer | 4 | $102 |
| Urovant Sciences Inc | 6 | $89 |
| Laborie Medical Technologies Corp. | 2 | $60 |
| Myriad Genetic Laboratories, Inc. | 4 | $60 |
| Travere Therapeutics, Inc. | 3 | $55 |
| Ferring Pharmaceuticals Inc. | 3 | $53 |
| Boston Scientific | 2 | $52 |
| Medtronic | 2 | $32 |
| Myovant Sciences Inc. | 2 | $27 |
| Alnylam Pharmaceuticals Inc. | 2 | $27 |
| Amgen | 1 | $23 |
| Intuitive Surgical | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $21 |
| Civco Medical Instruments | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Innovation Technologies Inc | 1 | $16 |
| Procept Biorobotics Corporation | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$122
How this compares
$3,176 in reported general payments places this provider in the 90th percentile of 121 surgical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 72 | $57,943 |
| Tamsulosin Hcl | 390 | $6,823 |
| Solifenacin Succinate | 137 | $3,964 |
| Methenamine Hippurate | 33 | $3,343 |
| NitrofurantoinNitrofurantoin Macrocrystal | 52 | $2,415 |
| Silodosin | 20 | $1,841 |
| Finasteride | 109 | $1,689 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 193 | $977 |
| Testosterone Cypionate | 23 | $960 |
| Bethanechol Chloride | 13 | $944 |
| Potassium Citrate ErPotassium Citrate | 12 | $912 |
| Dutasteride | 21 | $781 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $584 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 25 | $568 |
| Cephalexin | 61 | $481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $460 | $57,94372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 121 surgical providers in Utah.
Other surgical in American Fork
- Stephen LoperAmerican Fork$5K
- Lindsay AdamsAmerican Fork$3K
- Jonathan BrownAmerican Fork$3K
- Scott HadfieldSalt Lake City$10K
- Brittany CrossSalt Lake City$6K
- Jason HoldenDraper$6K
- Drew LambourneProvo$4K
- Brittney TaylorSalt Lake City$4K
- Richard ClowardOgden$4K
- David TranterDraper$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.